RASBURICASE
(Fasturec; Elitek; urate oxidase)Standard Prescription
rasburicase __mg IV Q__H (__mg/kg/dose)
Dosages
Children: 0.15 to 0.2 mg/kg/dose IV once. Monitor uric acid level and repeat dose if elevated. One dose may be sufficient. Maximum one dose per 24 hours if uric acid level is normal
During therapy, uric acid blood samples must be sent to the lab immediately in prechilled tubes and kept in an ice-water bath to avoid potential falsely low uric acid levels (degradation of plasma uric acid occurs in the presence of
rasburicase at room temperature).
During therapy, uric acid blood samples must be sent to the lab immediately in prechilled tubes and kept in an ice-water bath to avoid potential falsely low uric acid levels (degradation of plasma uric acid occurs in the presence of
rasburicase at room temperature).
Mechanism of Action
Urate-oxidase enzyme; promotes degradation of uric acid
Forms Supplied
injection: 1.5 mg/vial
Comments
Indicated for the prevention of renal failure from hyperuricemia in tumor lysis syndrome (TLS).
Patients most at risk for renal failure from TLS are those with leukemia and a very high WBC (>50,000100,000) and those with bulky lymphomas.
Rasburicase affects only uric acid levels; it has no effect on hyperphosphatemia or hyperkalemia.
Doses should be rounded down to nearest 1.5 mg vial size.
Onset of effect: within 4 hours
Contraindicated in G6PD deficiency.
Children < 2 yrs of age may have a higher incidence of adverse effects, particularly vomiting, diarrhea, fever and rash.
Patients most at risk for renal failure from TLS are those with leukemia and a very high WBC (>50,000100,000) and those with bulky lymphomas.
Rasburicase affects only uric acid levels; it has no effect on hyperphosphatemia or hyperkalemia.
Doses should be rounded down to nearest 1.5 mg vial size.
Onset of effect: within 4 hours
Contraindicated in G6PD deficiency.
Children < 2 yrs of age may have a higher incidence of adverse effects, particularly vomiting, diarrhea, fever and rash.
Rasburicase may cause severe hypersensitivity reactions, including anaphylaxis. Discontinue immediately and permanently in any patient showing signs and symptoms of severe allergy such as chest pain, dyspnea, hypotension and/or urticaria.
Administer as a single course of rasburicase per lifetime due to risk of serious anaphylactic reactions.
References
44, 116, 388
Last Edited
2022-04-23 06:31:15